{
  "pmcid": "12485508",
  "sha256": "0f6ccb2832acea9648f99123ace1126691fe10c50dd58df4dac36e208fe4487c",
  "timestamp_utc": "2025-11-09T23:41:11.639746+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 13.41416666666667,
    "reading_ease": 27.387500000000017,
    "word_count": 240
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of STS-PROM in Predicting Stroke and Neurocognitive Outcomes Post-TAVR"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Patient-level data were pooled from four prospective trials"
      },
      "Participants": {
        "score": 1,
        "evidence": "537 of 603 patients who underwent TAVR"
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were stratified into low (<4%), intermediate (4-8%), and high (>8%) STS risk groups."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluates whether the Society of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM) predicts stroke and neurocognitive outcomes following transcatheter aortic valve replacement (TAVR)."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "At 30 days, high-risk patients had higher rates of all-cause and cardiovascular mortality"
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "537 of 603 patients who underwent TAVR"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "The mean STS score among patients with versus without stroke was similar (5.9 vs 5.1; p = 0.19)."
      },
      "Harms": {
        "score": 1,
        "evidence": "high-risk patients had higher rates of all-cause and cardiovascular mortality, myocardial infarction, acute kidney injury, bleeding, and vascular complications."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "DEFLECT III (NCT02070731), NeuroTAVR (NCT02073864), REFLECT I (NCT02536196), REFLECT II (NCT02536196)."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 13,
    "max_score": 25
  }
}